PMID- 23814462
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130702
LR  - 20211021
IS  - 1177-889X (Print)
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 7
DP  - 2013
TI  - Triple-combination rilpivirine, emtricitabine, and tenofovir 
      (Complera/Eviplera) in the treatment of HIV infection.
PG  - 531-42
LID - 10.2147/PPA.S28797 [doi]
AB  - The combination rilpivirine (RPV)/emtricitabine (FTC)/tenofovir (TDF) is a 
      once-daily, single-tablet regimen (STR) containing one nonnucleoside 
      reverse-transcriptase inhibitor associated with two nucleos(t)ide reverse 
      transcriptase inhibitors. It is approved by regulatory agencies (eg, US Food and 
      Drug Association, European Medicines Agency) in all countries in which it is 
      manufactured, except Switzerland, as first-line highly active antiretroviral 
      therapy (HAART) for the treatment of naive patients with HIV infection and a 
      viral load HIV-RNA level of </=100,000 copies/mL. Two large trials (ECHO and 
      THRIVE) comparing RPV with efavirenz, along with different background regimens, 
      led to approval of the drug, while a more recent trial (STaR) explored the use of 
      STR. RPV showed noninferiority to efavirenz in all the studies, including 
      superiority as an STR in patients with HIV-RNA </=100,000 copies/mL in the STaR 
      study. A positive CD4 cell response was observed in all the studies, both in the 
      RPV and efavirenz groups. The incidence of virologic failures was higher for RPV, 
      but was mostly referred to patients with HIV-RNA >100,000 copies/mL. There were 
      fewer adverse events (AEs) with the RPV-based regimens versus efavirenz-based 
      regimens, with a lower discontinuation rate because of AEs, especially 
      psychiatric-neurological AEs, and a significantly lower rate of blood-lipid 
      abnormalities. In the SPIRIT study (a switch study), significantly greater 
      improvements from baseline in serum total cholesterol, low-density lipoprotein 
      cholesterol, and trygliceride were demonstrated in patients switching to 
      RPV/FTC/TDF from a ritonavir-boosted protease inhibitor (PI/r)-based regimen, 
      than in those who continued treatment with a PI/r regimen. RPV's better 
      tolerability, associated with its once-daily STR formulation, is key to improving 
      patients' adherence and quality of life, which are among the most important 
      factors affecting the therapeutic efficacy of an antiretroviral regimen. In 
      summary, RPV/FTC/TDF STR is a valuable treatment option for the majority of 
      antiretroviral-naive HIV-infected patients. Furthermore, the use of this STR in 
      the therapeutic switch, like in the SPIRIT study, can result in another valuable 
      option by which to reduce AEs and improve patients' quality of life.
FAU - Bernardini, Claudia
AU  - Bernardini C
AD  - Division of Infectious Diseases and Unit of Antiviral Therapy, AO Papa Giovanni 
      XXIII, Bergamo, Italy.
FAU - Maggiolo, Franco
AU  - Maggiolo F
LA  - eng
PT  - Journal Article
DEP - 20130619
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC3693919
OTO - NOTNLM
OT  - HIV
OT  - once-daily
OT  - rilpivirine or RPV
OT  - single-tablet regimen
OT  - treatment-naive
EDAT- 2013/07/03 06:00
MHDA- 2013/07/03 06:01
PMCR- 2013/06/19
CRDT- 2013/07/02 06:00
PHST- 2013/07/02 06:00 [entrez]
PHST- 2013/07/03 06:00 [pubmed]
PHST- 2013/07/03 06:01 [medline]
PHST- 2013/06/19 00:00 [pmc-release]
AID - ppa-7-531 [pii]
AID - 10.2147/PPA.S28797 [doi]
PST - epublish
SO  - Patient Prefer Adherence. 2013 Jun 19;7:531-42. doi: 10.2147/PPA.S28797. Print 
      2013.